Evoke Pharma Price to Sales Ratio 2012-2023 | EVOK
Historical PS ratio values for Evoke Pharma (EVOK) over the last 10 years. The current P/S ratio for Evoke Pharma as of May 03, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Evoke Pharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-05-03 |
0.49 |
|
0.36 |
| 2023-12-31 |
1.05 |
$1.34 |
0.79 |
| 2023-06-30 |
1.65 |
$1.08 |
1.52 |
| 2023-03-31 |
1.90 |
$0.89 |
2.13 |
| 2022-12-31 |
2.68 |
$0.80 |
3.34 |
| 2022-09-30 |
1.87 |
$0.68 |
2.74 |
| 2022-06-30 |
3.24 |
$0.90 |
3.59 |
| 2022-03-31 |
5.94 |
$1.10 |
5.41 |
| 2021-12-31 |
6.60 |
$1.03 |
6.39 |
| 2023-09-30 |
1.38 |
$0.93 |
1.48 |
| 2021-09-30 |
15.60 |
$0.47 |
33.51 |
| 2021-06-30 |
16.44 |
$0.12 |
134.21 |
| 2021-03-31 |
21.96 |
$0.03 |
630.50 |
| 2020-12-31 |
30.96 |
0 |
0.00 |
| 2020-09-30 |
56.28 |
0 |
0.00 |
| 2020-06-30 |
42.48 |
0 |
0.00 |
| 2020-03-31 |
13.92 |
0 |
0.00 |
| 2019-12-31 |
19.44 |
0 |
0.00 |
| 2019-09-30 |
10.32 |
0 |
0.00 |
| 2019-06-30 |
7.50 |
0 |
0.00 |
| 2019-03-31 |
18.00 |
0 |
0.00 |
| 2018-12-31 |
29.76 |
0 |
0.00 |
| 2018-09-30 |
35.76 |
0 |
0.00 |
| 2018-06-30 |
30.00 |
0 |
0.00 |
| 2018-03-31 |
24.96 |
0 |
0.00 |
| 2017-12-31 |
27.12 |
0 |
0.00 |
| 2017-09-30 |
40.08 |
0 |
0.00 |
| 2017-06-30 |
30.70 |
0 |
0.00 |
| 2017-03-31 |
37.20 |
0 |
0.00 |
| 2016-12-31 |
24.24 |
0 |
0.00 |
| 2016-09-30 |
27.12 |
0 |
0.00 |
| 2016-06-30 |
82.20 |
0 |
0.00 |
| 2016-03-31 |
61.08 |
0 |
0.00 |
| 2015-12-31 |
39.60 |
0 |
0.00 |
| 2015-09-30 |
34.92 |
0 |
0.00 |
| 2015-06-30 |
62.76 |
0 |
0.00 |
| 2015-03-31 |
84.60 |
0 |
0.00 |
| 2014-12-31 |
70.80 |
0 |
0.00 |
| 2014-09-30 |
65.99 |
0 |
0.00 |
| 2014-06-30 |
97.08 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
